Did GC’s Departure Bring On A Legal Mess For Genetic Testing Firm?

In November, the FDA asked 23andMe to stop selling and marketing its genetic testing kit, citing lack of testing data and a high number of false positives for diseases including Alzheimer’s and Parkinson’s. As general counsel, Ashely Gould appears to have initiated contact with the FDA in 2012, but she left the company in July of this year.  The company is still looking for a new GC, and MedCity News suggests that with CEO Anne Wojcicki focused on science and research and the legal team now reporting to a new hire whose major expertise and experience appears to be in marketing and advertising, the stage was set for regulatory problems. The company has agreed to stop selling its $99 kit.